Advicenne SA
3MM
Company Profile
Business description
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
Contact
262, rue du Faubourg Saint-Honor
Paris75008
FRAT: +33 185733620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,884.50 | 32.60 | -0.37% |
| CAC 40 | 7,811.26 | 110.42 | -1.39% |
| DAX 40 | 25,371.75 | 273.29 | -1.07% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,725.03 | 27.85 | -0.26% |
| HKSE | 22,934.68 | 717.19 | -3.03% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,105.31 | 802.53 | -1.28% |
| NZX 50 Index | 13,710.49 | 36.35 | -0.26% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,774.20 | 19.00 | -0.22% |
| SSE Composite Index | 3,656.71 | 1.31 | -0.04% |